57699-91-9

Basic information

• Product Name: Pyrazolidine, N1-BOC protected
• Synonyms: tert-Butyl pyrazolidine-1-carboxylate, 1-(tert-Butoxycarbonyl)pyrrazolidine;1-pyrazolidinecarboxylate;Tert-butyl Pyrazolidine, N1-BOC protected;tert-Butyl 1-pyrazolidinecarboxylate;tert-Butyl pyrazolidine-1-carboxylate;1-Butyl-1-pyrazolidinecarboxylate;1-Pyrazolidinecarboxylic acid, 1,1-diMethylethyl ester
• CAS NO: 57699-91-9
• Molecular Formula: C₈H₁₆N₂O₂
• Molecular Weight: 172.22484
• Mol File: 57699-91-9.mol

Chemical Properties

• Boiling Point: 214.636 °C at 760 mmHg
• Flash Point: 83.609 °C
• Appearance: /
• Density: 1.057 g/cm³
• Vapor Pressure: 0.154mmHg at 25°C
• Refractive Index: 1.471
• PKA: 4.42±0.20(Predicted)
• CAS DataBase Reference: Pyrazolidine, N1-BOC protected(CAS DataBase Reference)
• NIST Chemistry Reference: Pyrazolidine, N1-BOC protected(57699-91-9)
• EPA Substance Registry System: Pyrazolidine, N1-BOC protected(57699-91-9)

Safety Data

• Hazard Codes: Xi
• HazardClass: IRRITANT
• Hazardous Substances Data: 57699-91-9(Hazardous Substances Data)

Usage

Uses

Used in Organic Synthesis:
Pyrazolidine, N1-BOC protected, is used as a building block for the synthesis of various organic compounds. The BOC protecting group allows for selective reactions to occur at other sites on the molecule, while the free amine can be accessed after removal of the protecting group.
Used in Pharmaceutical Research:
In the pharmaceutical industry, Pyrazolidine, N1-BOC protected, is used as a key intermediate in the development of new drugs and biologically active molecules. The protecting group facilitates the synthesis of complex molecules with specific functional groups, enabling the exploration of novel therapeutic agents.
Used in Drug Development:
Pyrazolidine, N1-BOC protected, is employed in the design and synthesis of potential drug candidates. The versatility of the protecting group allows for the creation of diverse chemical structures, which can be optimized for improved pharmacological properties, such as potency, selectivity, and bioavailability.
Used in Medicinal Chemistry:
In medicinal chemistry, Pyrazolidine, N1-BOC protected, serves as a versatile scaffold for the construction of bioactive molecules. The protecting group enables the synthesis of compounds with specific pharmacophores, which can be further modified to enhance their biological activity and therapeutic potential.
Overall, Pyrazolidine, N1-BOC protected, is a valuable chemical entity in the fields of organic synthesis, pharmaceutical research, drug development, and medicinal chemistry, owing to its unique protecting group and potential applications in the creation of novel and effective therapeutic agents.

InChI:InChI=1/C8H16N2O2/c1-8(2,3)12-7(11)10-6-4-5-9-10/h9H,4-6H2,1-3H3

Upstream product

• 870-46-2 t-butoxycarbonylhydrazine 
• 504-70-1 pyrazolidine 
• 24424-99-5 di-tert-butyl dicarbonate 
• 109-64-8 1,3-dibromo-propane 
• 57699-88-4 1-tert-butoxycarbonyl-2-carbobenzyloxyhydrazine 
• 57699-89-5 pyrazolidine-1,2-dicarboxylic acid 1-benzyl ester 2-tert-butyl ester 

Downstream Products

• 159174-58-0 N-benzyloxycarbonyl-L-phenylalanyl-α-azaproline tert-butyl ester 
• 443295-23-6 tert-butyl 2-(4-chlorobenzoyl)pyrazolidine-1-carboxylate 
• 714251-89-5 Boc-AzaPro-Phe-OBn 
• 1181083-16-8 C₁₈H₂₀FN₃O₄S 
• 706778-85-0 2-[3-(benzyloxyformylamino)-(2R)-cyclopentylmethyl-propionyl]-pyrazolidine-1-carboxylic acid tert-butyl ester 
• 222854-34-4 1-tert-butyl 2-(9H-fluoren-9-ylmethyl) pyrazolidine-1,2-dicarboxylate 
• 1026336-36-6 N-<(R)-2-(p-nitrophenoxy)carbonyloxy>propionyl-L-phenylalanyl-α-azaproline tert-butyl ester 
• 159174-59-1 N-<(R)-2-benzyloxypropionyl>-L-phenylalanyl-α-azaproline tert-butyl ester 
• 159174-67-1 N-<(2'S)-2'-<(5''R)-5''-methyl-2'',4''-dioxooxazolidin-3''-yl>-3'-phenylpropionyl>-α-azaproline tert-butyl ester 
• 159174-66-0 N-<(R)-2-hydroxypropionyl>-L-phenylalanyl-α-azaproline tert-butyl ester 
• 159174-54-6 N-(tert-butoxycarbonyl)-α-azaprolyl-L-phenylalanine methyl ester 
• 159174-60-4 L-phenylalanyl-α-azaproline tert-butyl ester 
• 500770-98-9 Boc-azPro-tritylamide 
• 849925-83-3 2-benzyl-pyrazolidine-1-carboxylic acid tert-butyl ester 

Relevant articles and documents

Amidines analogs thereof to catalyze the nitrogen mixed fat surrounds uncle-butoxy carbonyl list protection method (by machine translation)

The present invention is a method under the catalysis of the analogs of the amidines, to two nitrogen heterolipid animal fat link Boc protection of single green synthesis method. It is characterized in that the various two nitrogen heterolipid animal fat link compound water and alcohol as the solvent, in the presence of a certain amount of acid, joins the trunk and its analogs catalyst, di-T-butyl ester for (Boc anhydride) as Boc protecting reagent, the temperature of the reaction is carried out, the final by reduced pressure distillation to obtain the target product is separated from the single N - Boc - two nitrogen heterolipid [...] compound. The invention innovative use of the amidines its analogues as single Boc protecting catalyst, more traditional synthetic method more green environmental protection, safety, and cost saving. (by machine translation)

METHOD OF DRUG DESIGN AND OPTIMISATION UTILIZING STEREOCHEMICAL MIMICRY

The invention relates to a method of designing or optimizing a drug candidate by making stereodynamic derivatives as well as novel derivatives of Glyx-13 with improved biological and pharmacological properties.

Peptidomimetic inhibitors of bacterial peptide deformylase

A series of N-formyl hydroxylamine peptide deformylase inhibitors containing a cyclic azaamino acid moiety between the P1′ and P3′ substituents are presented. Selected compounds display antibacterial activity against pathogens associated with respiratory

FXA INHIBITORS WITH CYCLIC AMIDOXIME OR CYCLIC AMIDRAZONE AS P4 SUBUNIT, PROCESSES FOR THEIR PREPARATIONS, AND PHARMACEUTICAL COMPOSITIONS AND DERIVATIVES THEREOF

The present invention relates to novel oxazolidinone derivatives with cyclic amidoxime or cyclic amidrazone group, pharmaceutically acceptable salts thereof, methods for preparing the same and pharmaceutical compositions comprising the same. The oxazolidinone derivatives with cyclic amidoxime or cyclic amidrazone group or the pharmaceutically acceptable salts thereof can be effectively used for the treatment of thromboembolism and tumor as an anticoagulant based on the inhibition of factor Xa.

FXA INHIBITORS WITH CYCLIC AMIDOXIME OR CYCLIC AMIDRAZONE AS P4 SUBUNIT, PROCESSES FOR THEIR PREPARATIONS, AND PHARMACEUTICAL COMPOSITIONS AND DERIVATIVES THEREOF

The present invention relates to novel oxazolidinone derivatives with cyclic amidoxime or cyclic amidrazone group, pharmaceutically acceptable salts thereof, methods for preparing the same and pharmaceutical compositions comprising the same. The oxazolidinone derivatives with cyclic amidoxime or cyclic amidrazone group or the pharmaceutically acceptable salts thereof can be effectively used for the treatment of thromboembolism and tumor as an anticoagulant based on the inhibition of factor Xa.

Development of cyclic hydrazine and hydrazide type organocatalyst-mechanistic aspects of cyclic hydrazine/hydrazide-catalyzed diels-alder reactions

Some hydrazines and hydrazides were prepared and screened for their catalytic efficiencies in Diels-Alder reactions. 1H-NMR studies and ab initio calculations revealed that catalytic efficiencies of these catalysts are greatly dependent on the release of the catalysts from the Diels-Alder adducts.

Synthesis and evaluation of pyrazolidine derivatives as dipeptidyl peptidase IV (DP-IV) inhibitors

A new series of pyrazolidine derivatives was synthesized and evaluated for their ability to inhibit dipeptidyl peptidase IV (DP-IV). Compound 9i was the most active in this series, exhibited IC50 value of 1.56 μM and ED50 value of 80

Aza-amino acid scan for rapid identification of secondary structure based on the application of N-Boc-aza1-dipeptides in peptide synthesis

Azapeptides, peptide analogues in which the α-carbon of one or more of the amino acid residues is replaced with a nitrogen atom, exhibit propensity for adopting β-turn conformations. A general protocol for the synthesis of azapeptides without racemization on solid phase has now been developed by introducing the aza-amino acid residue as an N-Boc-aza1-dipeptide. This approach has been validated by the synthesis of six N-Boc-aza 1-dipeptides and their subsequent introduction into analogues of the C-terminal peptide fragment of the human calcitonin gene-related peptide (hCGRP). By performing an aza-amino acid scan of such antagonist peptides, a set of aza-hCGRP analogues was synthesized to examine the relationship between turn secondary structure and biological activity.

Impact of azaproline on amide cis-trans isomerism: Conformational analyses and NMR studies of model peptides including TRH analogues

The β-turn is a well-studied motif in both proteins and peptides. Four residues, making almost a complete 180°-turn in the direction of the peptide chain, define the β-turn. Several types of the β-turn are defined according to Φ and Ψ torsional angles of

Cyclic dibenzoylhydrazines reproducing the conformation of ecdysone agonists, RH-5849

We have investigated the biologically active conformation of the non-steroidal ecdysone agonist, 1-tert-butyl-1,2-dibenzoylhydrazine (RH-5849) by means of design, synthesis and conformational analysis of cyclic derivatives of RH-5849. Among the synthesize